Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex & ORCID
How has Uli C. Broedl's publication output changed over time?
ScholarIQpublication output · 2008–2021
Output grew0% over the shown period — from 1 works in 2008 to 1 in 2021.
1
1
3
3
2
1
1
2008201320142015201620172021
What are the most-cited papers on Uli C. Broedl?
ScholarIQmost cited works
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Bernard Zinman, Christoph Wanner, John M. Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J. Woerle, Uli C. Broedl, Silvio E. Inzucchi
New England Journal of Medicine. 201512,121 CitationsOPEN ACCESS
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Christoph Wanner, Silvio E. Inzucchi, John M. Lachin, David Fitchett, Maximilian von Eynatten, Michaela Mattheus, Odd Erik Johansen, Hans J. Woerle, Uli C. Broedl, Bernard Zinman
New England Journal of Medicine. 20163,655 CitationsOPEN ACCESS
Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus
David Z.I. Cherney, Bruce A. Perkins, Nima Soleymanlou, M Maione, Vesta Lai, Alana Lee, Nora Fagan, Hans J. Woerle, Odd Erik Johansen, Uli C. Broedl, Maximilian von Eynatten
Circulation. 20131,319 CitationsOPEN ACCESS
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients
Ele Ferrannini, Elza Muscelli, Silvia Frascerra, Simona Baldi, Andrea Mari, Tim Heise, Uli C. Broedl, Hans‐Juergen Woerle
S114430552. 20141,137 CitationsOPEN ACCESS
Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME <sup>®</sup> trial
David Fitchett, Bernard Zinman, Christoph Wanner, John M. Lachin, Stefan Hantel, Afshin Salsali, Odd Erik Johansen, Hans J. Woerle, Uli C. Broedl, Silvio E. Inzucchi
European Heart Journal. 2016906 CitationsOPEN ACCESS
Related on ScholarIQ
Boehringer Ingelheim (United States)
Institution
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Paper
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Paper
Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus
Paper
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients
Paper
Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME <sup>®</sup> trial
Paper